BUND FINANCE

BUND FINANCE › Stocks › VRTX

Vertex Pharmaceuticals Incorporated (VRTX)

NASDAQ · Stock price, chart and technical analysis

US$536.45+2.25 (+0.42%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$534.20
OpenUS$532.27
Day rangeUS$531.43 – US$542.76
52-week rangeUS$412.27 – US$568.67
Market capUS$136.01B
Volume1.29M
50-day averageUS$522.31
200-day averageUS$483.99
Beta0.32

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$7.6BUS$8.9BUS$9.9BUS$11.0BUS$12.0B
Net incomeUS$2.3BUS$3.3BUS$3.6B−US$535.6MUS$4.0B
EPS (diluted)9.0112.8213.89-2.0815.32
Gross margin88.1%87.9%87.2%86.1%86.2%
Operating margin36.7%48.2%38.8%-2.1%34.8%
Net margin30.9%37.2%36.7%-4.9%32.9%
Free cash flowUS$2.4BUS$3.9BUS$3.3B−US$790.3MUS$3.2B
Total debtUS$967.4MUS$899.7MUS$808.4MUS$1.7BUS$2.0B
CashUS$6.8BUS$10.5BUS$10.4BUS$4.6BUS$5.1B

Compound annual growth: revenue 12.2% · net income 14.0% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E34.5x26.2x27.1x
EV / EBITDA27.4x57.2x16.5x
Operating margin33.9%—3.6%
Net margin30.6%—-0.0%
Debt / equity0.57—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Vertex Pharmaceuticals Incorporated

SectorHealthcare
IndustryBiotechnology
CountryUS
CEOReshma Kewalramani
Employees6,400
IPO date1991-07-24

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitryp…

www.vrtx.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice